Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study
S Lori1, E Portaccio, V Zipoli
1Department of Neurophysiopathology, Careggi Hospital, Florence, Italy.
Summary
Pediatric multiple sclerosis (MS) patients show cognitive decline linked to P300 event-related potential changes. This neurophysiological marker may help monitor cognitive function in children and adolescents with MS.
Area of Science:
- Neuroscience
- Pediatric Neurology
- Clinical Neurophysiology
Background:
- Multiple sclerosis (MS) onset before 18 years affects 3-10% of patients.
- Cognitive impairment is a significant concern in pediatric MS, but its neurophysiological basis is understudied.
- Event-related potentials (ERPs) offer a potential window into brain function.
Purpose of the Study:
- To investigate the relationship between event-related potentials (ERPs) and cognitive performance in pediatric MS patients.
- To compare neurophysiological correlates of cognition in children and adolescents with MS versus healthy controls (HC).
- To provide two-year follow-up data on cognitive and neurophysiological changes.
Main Methods:
- Assessed six pediatric MS patients (ages 9-17) using a comprehensive neuropsychological battery at two time points.
- Recorded event-related potentials (ERPs) using an odd-ball acoustic paradigm in patients and nine HC.
- Classified patients as cognitively impaired based on performance on multiple cognitive tasks.
Main Results:
- At baseline, 4/6 pediatric MS patients were cognitively impaired, showing abnormal P300 latencies and amplitudes.
- After two years, 5/6 patients showed cognitive deterioration, paralleled by worsening P300 parameters.
- Abnormal P300 findings correlated with cognitive deficits in pediatric MS.
Conclusions:
- Changes in P300 parameters in pediatric MS patients occur in parallel with cognitive performance decline.
- The P300 component of event-related potentials may serve as an objective biomarker for monitoring cognitive changes in pediatric MS.
- Further research is warranted to validate P300 as a clinical tool for pediatric MS management.

